Evolving use of new oral anticoagulants for treatment of venous thromboembolism
Open Access
- 14 August 2014
- journal article
- review article
- Published by American Society of Hematology in Blood
- Vol. 124 (7) , 1020-1028
- https://doi.org/10.1182/blood-2014-03-563056
Abstract
The new oral anticoagulants (NOACs), which include dabigatran, rivaroxaban, apixaban, and edoxaban, are poised to replace warfarin for treatment of tKeywords
This publication has 46 references indexed in Scilit:
- Oral Apixaban for the Treatment of Acute Venous ThromboembolismNew England Journal of Medicine, 2013
- Apixaban for Extended Treatment of Venous ThromboembolismNew England Journal of Medicine, 2013
- Extended Use of Dabigatran, Warfarin, or Placebo in Venous ThromboembolismNew England Journal of Medicine, 2013
- Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studiesThrombosis Journal, 2013
- Intracranial Hemorrhage in Atrial Fibrillation Patients During Anticoagulation With Warfarin or DabigatranStroke, 2012
- Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary EmbolismNew England Journal of Medicine, 2012
- Dabigatran and risk of myocardial infarctionNature Reviews Cardiology, 2012
- Antithrombotic Therapy for VTE DiseaseChest, 2012
- Newly Identified Events in the RE-LY TrialNew England Journal of Medicine, 2010
- Incidence rates, clinical profile, and outcomes of patients with venous thromboembolism. The Worcester VTE studyJournal of Thrombosis and Thrombolysis, 2009